Tests a spinal cord stimulation device for walking problems in Parkinson's disease
Tests the ARC-IM spinal stimulation device to ease leg movement problems in adults with Parkinson's.
Plain-language title generated from the registry record
Registry title: Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease
Key facts
- Where
- Lausanne, SwitzerlandSee the site
Where in Switzerland
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ecole Polytechnique Fédérale de Lausanne
- Trial code
- NCT06295614
- Record updated
- 4 June 2026
- Original description
The purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease. The ARC-IM Therapy employs epidural electrical stimulation (EES) to modulate leg muscle recruitment, with the aim of improving mobility deficits. The ultimate goal is to enhance the quality of life of people with Parkinson's disease.Read full original descriptionShow less
Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease
The purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease. The ARC-IM Therapy employs epidural electrical stimulation (EES) to modulate leg muscle recruitment, with the aim of improving mobility deficits. The ultimate goal is to enhance the quality of life of people with Parkinson's disease.
Inclusion: Typical form of Parkinson's Disease with II-IV Hoehn-Yahr stage with standard therapy,; Suffering from debilitating locomotor deficits, including gait impairments of either postural instability and/or freezing of gait, despite optimal medical management,; 18 years of age or older,; Able to understand and interact with the study team in French or English,; Must use safe contraception for women of childbearing capacity,; Must agree to comply in good faith with all conditions of the study and to attend all required study trainings and visits; Must provide and sign the study's Informed Consent prior to any study-related procedures.
Exclusion: Spinal anatomical abnormalities precluding surgery,; Atypical forms of Parkinson's Disease (such as Multiple System Atrophy or Progressive Supranuclear Palsy),; Secondary causes of gait problems independent of Parkinson's Disease,; Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator,; History of major psychiatric disorders or major neurocognitive disorder as considered by the Investigators in accordance with treating physician and treating neurologist,; Diseases and conditions that would increase the morbidity and mortality of the implantation surgery,; History of drug or alcohol abuse in the past 5 years,; Inability to follow study procedures,; Major change in PD treatment planned until the end of the main study phase (such as Deep Brain Stimulation or dopamine-pump implantation),; Life expectancy of less than 12 months,; Pregnant or breast feeding,; Intention to get pregnant during the course of the study,; Indication requiring frequent Magnetic Resonance Imaging (MRI),; Experimental treatment taken in the past 5 years,; Participation in another interventional study,; Enrolment of the investigator, his/her family members, employees, and other dependent persons.